A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

This study has been completed.
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
First received: January 5, 2009
Last updated: June 7, 2012
Last verified: July 2011

A recent report has demonstrated improvements in QoL parameters in patients receiving TYSABRI® (Rudick et al, 2007). This observation, coupled with anecdotal reports and our own experience, lead us to hypothesize that TYSABRI® will have a demonstrable beneficial effect on improving patient's bladder function as defined by changes in baseline to month 6 scores on the UDI-6 and also on patient reported incontinence episodes and micturitions per day.

Relapsing Remitting Multiple Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Bladder Function in Relapsing Remitting Multiple Sclerosis Patients Treated With Natalizumab (TYSABRI)

Resource links provided by NLM:

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Change in bladder function as measured by UDI-6 compared to baseline over 6 months of TYSABRI® treatment. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline over 6 months of TYSABRI® treatment in the number of urinary incontinence episodes per patient per week. Mean change from baseline over 6 months of TYSABRI® treatment in the number of micturitions per patient per day. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: March 2009
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Patients who are newly prescribed TYSABRI®, but have not received their first infusion, will be invited to participate.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Men and women 18 years or older with relapsing remitting multiple sclerosis who have never received an infusion of TYSABRI.


Inclusion Criteria:

Patients are eligible to be screened for this study if all of the following criteria are met:

  • Patient must meet all prescribing criteria for TYSABRI® and eligible for the TOUCH™ program.
  • If utilizing medications for symptoms of bladder dysfunction (such as incontinence, urgency etc), subjects will need to remain on a stable dose of medication(s) for at least one month prior to and for duration of study.
  • If utilizing medications that affect urinary output (e.g. anticholinergics, diuretics, etc.), subjects will need to remain on a stable dose of medication(s) for at least one month prior to study entry and for the duration of the study.
  • Age 18 years or older.
  • Able to provide written informed consent.
  • Patient must be willing to maintain current hydration habits and caffeine intake for the duration of the study.

Patients will be selected for enrollment if all of the following criteria are met:

  • Screening Visit urinary incontinence defined as:

    - Greater than or equal to 3 incontinence episodes per week or greater than or equal to 8 micturitions per day (both mean numbers).

  • Screening Visit score on the UDI-6 of more than or equal to 6.
  • Screening Visit EDSS 0 - 6.5

Exclusion Criteria:

Candidates will be excluded from study screening if any of the following exclusion criteria exist:

  • Primary progressive, secondary progressive, or progressive relapsing MS. Primary progressive, secondary progressive or progressive relapsing multiple sclerosis are defined by Lublin and Reingold (Lublin and Reingold, 1996) or EDSS >6.5.
  • Current or previous history of Progressive Multifocal Leukencephalopathy (PML).
  • A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days.
  • History of recurrent or chronic urinary tract infection or a urinary tract infection within the preceding 30 days prior to Week 0 (diagnosis based on clinical history and Screening Visit urinalysis and urine culture).
  • Patients who have in-dwelling foley catheter or a suprapubic catheter.
  • Patients with a history of symptomatic benign prostatic hyperplasia (BPH) or a history of prostate cancer.
  • History of, or abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease, that, in the opinion of the investigator, would preclude the administration of natalizumab for the duration of the study.
  • Subject with history of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been treated.
  • History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
  • Any prior treatment with the following medications: Natalizumab (TYSABRI®)
  • Nursing mothers, pregnant women, and women planning to become pregnant while in study.
  • Any other reasons that, in the opinion of the Investigator and/or Sponsor, the subject is determined to be unsuitable for enrollment into this study.
  • Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.
  • History of alcohol or drug abuse within 2 years prior to randomization.
  • Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to use a medically acceptable method of birth control during the study. The rhythm method is not to be used as the sole method of contraception.
  • Age less than 18 years.

Patients will be determined as screen failures if any of the following criteria apply:

  • Abnormal blood tests, performed at the screening visit, which exceed any of the limits defined below:

    1. ALT/ SGPT, or AST/ SGOT more than three times the upper limit of normal (i.e., 3xULN).
    2. Total white blood cell (WBC) count less than 2,300/mm3.
    3. Platelet count less than 100,000/mm3.
    4. Creatinine more than 2xULN.
  • Screening Visit urinary incontinence defined as less than 3 incontinence episodes per week or less than 8 micturitions per day (both mean numbers).
  • Screening Visit score on the UDI-6 of less than 6.
  • Screening Visit EDSS more than 6.5.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00818038

United States, Utah
John Foley, MD
Salt Lake City, Utah, United States, 84103
United States, Wisconsin
Bhupendra Khatri, MD
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Biogen Idec
  More Information

No publications provided

Responsible Party: Richard Kim, MD, Biogen Idec, Inc
ClinicalTrials.gov Identifier: NCT00818038     History of Changes
Other Study ID Numbers: US 006-08-NAT
Study First Received: January 5, 2009
Last Updated: June 7, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Biogen Idec:
Relapsing Remitting

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 16, 2014